Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNF[alpha] inhibitors

Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNF[alpha] inhibitors

Background B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. Met...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy Vol. 17; no. 382
Main Authors: Golinski, Marie-Laure, Vandhuick, Thibault, Derambure, Cñline, Frñret, Manuel, Lecuyer, Matthieu, Guillou, Clñment, Hiron, Ma, Boyer, Olivier, Le Loët, Xavier, Vittecoq, Olivier, Lequerrñ, Thierry
Format: Journal Article
Language:English
Published: BioMed Central Ltd 26-12-2015
Subjects:
Biological markers
Complications and side effects
Influence
Rheumatoid arthritis
Tumor necrosis factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. Methods RasGRP1 and RasGRP3 expression levels were measured by qRT-PCR and/or western-blot in peripheral blood mononuclear cells (PBMCs), in T and B cells from untreated RA patients and in RA patients treated by TNF[alpha] inhibitors. T and B cells from healthy controls (HC) were cultured with TNF[alpha], and TNF[alpha] receptors neutralizing antibodies to highlight the TNF[alpha] effects on RasGRP1 and RasGRP3 pathways. MAPK pathways and apoptosis were respectively analyzed using the Proteome Profiler arrays and flow cytometry. Results In PBMCs from RA patients, gene expression levels of RasGRP1 were invariant while RasGRP3 was downregulated under TNF[alpha] inhibitors and upregulated under TNF[alpha]. In T cells from RA patients, RasGRP1 was decreased and its gene expression level was correlated with disease activity. In T cells from HC, TNF[alpha] stimulation increased RasGRP1 gene expression level while it reduced RasGRP1 protein expression level. Bryostatin-1 experiments have confirmed that the TNF[alpha] effect observed on T cells proliferation was due to the decrease of RasGRP1 expression. Besides, RasGRP3 expression level increased in PBMCs from RA patients under TNF[alpha] and in B cells from HC leading us to conclude that RasGRP3 in B cells was modulated by TNF[alpha]. Conclusion This study demonstrates RasGRP1 dysregulation in RA patients while RasGRP3 is characterized as a biomarker linked to TNF[alpha] inhibitors. After binding to TNFR1, TNF[alpha] reduced RasGRP1 protein expression resulting in inhibition of T cell activation. Trial registration Clinicaltrials.gov NCT00234234, registered 04 November 2008; NCT00767325, registered 05 October 2005. Keywords: Rheumatoid arthritis, T cells, B cells, RasGRP, TNF[alpha] inhibitors
ISSN:1478-6354
DOI:10.1186/s13075-015-0894-9